The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Maxair     2-(hydroxymethyl)-6-[1- hydroxy-2-(tert...

Synonyms: PIRBUTEROL, pyrbuterol, Pirbuterolum, SureCN4819, AG-J-31139, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of pirbuterol hydrochloride


High impact information on pirbuterol hydrochloride

  • The density of beta-adrenergic receptors on lymphocytes from patients treated with pirbuterol was significantly depressed as compared with that of patients with heart failure of comparable severity but not treated with pirbuterol [1].
  • Pirbuterol (PB), an oral beta-adrenergic-receptor agonist, has the pharmacologic effects of vasodilation and positive inotropy [6].
  • Pirbuterol induced an increase in cardiac index (1.7 +/- 0.1 to 2.3 +/- 0.2 l/min/m2, p less than 0.05) and a fall in systemic vascular resistance (1884 +/- 118 to 1391 +/- 69 dyn-sec-cm-5, p less than 0.01) 2 hours after administration [2].
  • We studied the effects of 20-30 mg of oral pirbuterol on myocardial metabolic and hemodynamic parameters in 12 patients (six with coronary artery disease) with chronic CHF refractory to standard medical therapy [2].
  • Thus, oral pirbuterol provides beneficial hemodynamic effects in patients with severe left ventricular dysfunction and appears potentially useful for long-term management of low-output congestive heart failure [3].

Chemical compound and disease context of pirbuterol hydrochloride


Biological context of pirbuterol hydrochloride


Anatomical context of pirbuterol hydrochloride

  • Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol [1].
  • Studies of the receptor affinity of pirbuterol, timolol and nylidrin were carried out on iris-ciliary body membranes by competition binding with radioactive ligands [15].
  • Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure [16].

Associations of pirbuterol hydrochloride with other chemical compounds


Gene context of pirbuterol hydrochloride

  • We studied the effects of an oral beta2 selective bronchodilator, pirbuterol, in 12 male asthmatic patients over periods ranging from 6 to 23 months (mean, 13.8) [12].
  • A new beta-2 adrenoceptor agonist (pirbuterol) in the treatment of ischaemic heart failure [19].
  • Haemodynamic studies at rest and during exercise together with radionuclide ventriculography, pulmonary function and clinical well-being assessment were evaluated in ten patients with COPD and secondary pulmonary hypertension (mean PAP 25 mm Hg), before and after 6 months therapy with pirbuterol 20 mg thrice daily [20].
  • In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma [21].

Analytical, diagnostic and therapeutic context of pirbuterol hydrochloride


  1. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. Colucci, W.S., Alexander, R.W., Williams, G.H., Rude, R.E., Holman, B.L., Konstam, M.A., Wynne, J., Mudge, G.H., Braunwald, E. N. Engl. J. Med. (1981) [Pubmed]
  2. Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. Rude, R.E., Turi, Z., Brown, E.J., Lorell, B.H., Colucci, W.S., Mudge, G.H., Taylor, C.R., Grossman, W. Circulation (1981) [Pubmed]
  3. Hemodynamic effects of oral pirbuterol in chronic severe congestive heart failure. Awan, N.A., Evenson, M.K., Needham, K.E., Evans, T.O., Hermanovich, J., Taylor, C.R., Amsterdam, E., Mason, D.T. Circulation (1981) [Pubmed]
  4. Pirbuterol, a selecttve beta2 adrenergic bronchodilator. Moore, P.F., Constantine, J.W., Barth, W.E. J. Pharmacol. Exp. Ther. (1978) [Pubmed]
  5. Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. Ashutosh, K., Dev, G., Steele, D. Chest (1995) [Pubmed]
  6. Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. Weber, K.T., Andrews, V., Janicki, J.S., Likoff, M., Reichek, N. Circulation (1982) [Pubmed]
  7. Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study. Timmis, A.D., Bergman, G., Walker, L., Monaghan, M.J., Jewitt, D.E. International journal of cardiology. (1984) [Pubmed]
  8. Comparison of pirbuterol and pirbuterol and hydroxyzine in patients with reversible airway obstruction. Poppius, H., Lehti, H., Stenius-Aarniala, B. Eur. J. Clin. Pharmacol. (1979) [Pubmed]
  9. Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol. Kenakin, T.P., Ferris, R.M. J. Cardiovasc. Pharmacol. (1983) [Pubmed]
  10. A comparative trial of pirbuterol and Tedral in patients with reversible airway obstruction. Votteri, B.A., Melcher, L. Annals of allergy. (1979) [Pubmed]
  11. Maximum bronchodilator effect of pirbuterol and procaterol administered as sprays with and without an aerochamber. Solé, D., Villalba, S.R., Sestelo, M.R., Scalabrin, D.M., Soares, F.J., Naspitz, C.K. Revista paulista de medicina. (1993) [Pubmed]
  12. Long-term oral bronchodilator therapy of asthma with pirbuterol. Burki, N.K., Diamond, L. Clin. Pharmacol. Ther. (1978) [Pubmed]
  13. Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease. Richards, D.M., Brogden, R.N. Drugs (1985) [Pubmed]
  14. Pharmacokinetics and cardiopulmonary effects in dogs of sublingual pirbuterol, a new bronchodilator. Constantine, J.W., McIlhenny, H.M., Moore, P.F. J. Pharmacol. Exp. Ther. (1979) [Pubmed]
  15. Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin. Mittag, T.W., Tormay, A., Messenger, M., Podos, S.M. Invest. Ophthalmol. Vis. Sci. (1985) [Pubmed]
  16. Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. Canepa-Anson, R., Dawson, J.R., Kuan, P., Poole-Wilson, P.A., Sutton, G.C., Cockrill, B., Reuben, S.R. British journal of clinical pharmacology. (1987) [Pubmed]
  17. Pharmacological actions of various inotropic agents. Scholz, H. Eur. Heart J. (1983) [Pubmed]
  18. Comparison of the Maxair Autohaler to wet nebulizer in patients with acute asthma. Silverman, R., Sellers, J., Greene, S., Flaster, E., Colice, G. Chest (1998) [Pubmed]
  19. A new beta-2 adrenoceptor agonist (pirbuterol) in the treatment of ischaemic heart failure. Nelson, G.I., Silke, B., Barker, M.C., Saxton, C.A., Taylor, S.H. Eur. Heart J. (1982) [Pubmed]
  20. Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD. Neilly, J.B., Carter, R., Tweddel, A., Martin, W., Hutton, I., Banham, S.W., Stevenson, R.D. Respiratory medicine. (1989) [Pubmed]
  21. Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. Völkl, K.P., Kroll, V.M., Wiesemann, H.G., Schneider, B. Arzneimittel-Forschung. (1991) [Pubmed]
  22. Intravenous pirbuterol. Leier, C.V., Nelson, S., Huss, P., Bianchine, J.R., Olukotun, A.Y., Taylor, C.R., Salzburg, D.S. Clin. Pharmacol. Ther. (1982) [Pubmed]
  23. The effect of six months of daily treatment with the beta-2 agonist oral pirbuterol on pulmonary hemodynamics in patients with chronic hypoxic cor pulmonale receiving long-term oxygen therapy. Biernacki, W., Prince, K., Whyte, K., MacNee, W., Flenley, D.C. Am. Rev. Respir. Dis. (1989) [Pubmed]
  24. Beta 2-adrenergic dilation of conductance coronary arteries involves flow-dependent NO formation in conscious dogs. Hamdad, N., Ming, Z., Parent, R., Lavallée, M. Am. J. Physiol. (1996) [Pubmed]
WikiGenes - Universities